Locoid Patent Expiration

Locoid is a drug owned by Bausch Health Americas Inc. It is protected by 2 US drug patents filed in 2013 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 19, 2026. Details of Locoid's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7378405 Stabilized steroid composition and method for its preparation
Dec, 2026

(2 years from now)

Active
US7981877 Stabilized steroid composition and method for its preparation
Jan, 2025

(3 months from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Locoid's patents.

Given below is the list of recent legal activities going on the following patents of Locoid.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 20 Dec, 2022 US7981877
Payment of Maintenance Fee, 8th Year, Large Entity 03 Jan, 2019 US7981877
Expire Patent 24 Jun, 2016 US7378405
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 08 Jan, 2015 US7981877
Email Notification 31 Oct, 2012 US7981877
Change in Power of Attorney (May Include Associate POA) 31 Oct, 2012 US7981877
Correspondence Address Change 30 Oct, 2012 US7981877
Email Notification 24 Oct, 2012 US7378405
Change in Power of Attorney (May Include Associate POA) 24 Oct, 2012 US7378405
Post Issue Communication - Certificate of Correction 23 Oct, 2012 US7981877

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Locoid is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Locoid's family patents as well as insights into ongoing legal events on those patents.

Locoid's Family Patents

Locoid has patent protection in a total of 1 countries. It has a significant patent presence in the US with 100.0% of its patents being US patents. Click below to unlock the full patent family tree for Locoid.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Locoid's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 19, 2026 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Locoid Generics:

Hydrocortisone Butyrate is the generic name for the brand Locoid. 6 different companies have already filed for the generic of Locoid, with Taro Pharm Inds having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Locoid's generic

How can I launch a generic of Locoid before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Locoid's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Locoid's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Locoid -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
0.001 31 Aug, 2016 1 21 Nov, 2017 19 Dec, 2026 Eligible

Alternative Brands for Locoid

There are several other brand drugs using the same active ingredient (Hydrocortisone Butyrate) as Locoid. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Precision Dermat
Locoid Lipocream


Apart from brand drugs containing the same ingredient, some generics have also been filed for Hydrocortisone Butyrate, Locoid's active ingredient. Check the complete list of approved generic manufacturers for Locoid





About Locoid

Locoid is a drug owned by Bausch Health Americas Inc. Locoid uses Hydrocortisone Butyrate as an active ingredient. Locoid was launched by Bausch in 2007.

Approval Date:

Locoid was approved by FDA for market use on 18 May, 2007.

Active Ingredient:

Locoid uses Hydrocortisone Butyrate as the active ingredient. Check out other Drugs and Companies using Hydrocortisone Butyrate ingredient

Dosage:

Locoid is available in lotion form for topical use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.1% LOTION Discontinued TOPICAL